

**RECEIVED**  
**CENTRAL FAX CENTER**  
**AUG 03 2005**

## Clark & Elbing LLP

101 Federal Street  
Boston, MA 02110

Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046

**Date:** August 3, 2005

**To:** Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Facsimile No.:** 571-273-8300

**From:** Paul T. Clark  
Reg. No. 30,162

**Re:** U.S. Patent Application No. 10/030,351  
Attorney Docket No. 06727/008002

**Pages:** 3, Including fax cover sheet

**Message:** Kindly see attached.

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

**BEST AVAILABLE COPY**

RECEIVED  
CENTRAL FAX CENTER  
AUG 03 2005

PATENT  
ATTORNEY DOCKET NO. 06727/008002

Certificate of Transmission by Facsimile: Date of Transmission: August 3, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Examiner listed below, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated above.

Christine M. Colbert

Printed name of person mailing correspondence

Christine M. Colbert  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lindsay et al.

Art Unit: 1632

Serial No.: 10/030,351

Examiner: Valerie Bertoglio

Filed: June 7, 2002

Customer No.: 21559

Title: EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN  
IN TRANSGENIC ANIMALS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

I, Robert Mulroy, hereby certify that I am authorized to act on behalf of Merrimack Pharmaceuticals, Inc. in matters before the United States Patent and Trademark Office. I further certify that Merrimack Pharmaceuticals, Inc. is the Assignee of the entire right, title, and interest in the above-identified United States patent application by virtue of the assignment recorded at Reel 016325, Frame 0066.

In the above-identified United States patent application, I hereby revoke all powers of attorney previously granted in the application and appoint the attorneys and/or agents associated with customer number 21559 with full power of substitution and revocation, to

BEST AVAILABLE COPY

FROM : MERRIMACK

FAX NO. :

Aug. 03 2005 07:11AM P3


prosecute the application and to transact all business in the United States Patent and Trademark Office connected herewith.

All correspondence regarding the application should be sent to the address associated with customer number 21559, which is Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Date: August 2, 2005

  
Robert Mulroy  
President and CEO  
Merrimack Pharmaceuticals, Inc.

BEST AVAILABLE COPY